Physician profile
Rajani R Caesar
NPI 1104020700
$4,470.83
in general payments reported to CMS, 2019-2025
32 companies · $96.91 in 2025
The $96.91 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $119 · 2021: $985 · 2022: $2,302 · 2023: $243 · 2024: $147 · 2025: $96.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $486.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,992.60 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $512.86 | 2021-2025 | Ubrelvy, Qulipta |
| Supernus Pharmaceuticals, INC. | $184.08 | 2019-2022 | |
| Allergan, INC. | $175.79 | 2019-2020 | |
| Biogen, INC. | $141.01 | 2021-2022 | |
| Lilly USA, LLC | $131.02 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $127.55 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $108.77 | 2019-2022 | |
| Sk Life Science, INC. | $97.93 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $92.79 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $92.57 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $84.88 | 2020-2021 | |
| Ucb, INC. | $80.38 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $71.89 | 2019 | |
| Lundbeck LLC | $66.22 | 2022-2025 | Vyepti, Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $60.39 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $49.48 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.39 | 2022 | |
| Pfizer INC. | $41.25 | 2023-2024 | |
| Genentech USA, INC. | $39.60 | 2021-2023 | Enspryng, Ocrevus |
| Amgen INC. | $35.55 | 2021-2022 | |
| Genzyme Corporation | $34.21 | 2021-2022 | |
| Grifols USA, LLC | $30.05 | 2021-2022 | |
| Ge Healthcare | $27.21 | 2022 | |
| Emd Serono, INC. | $26.38 | 2022 | |
| Mdd US Operations, LLC | $24.32 | 2022 | |
| Impel Pharmaceuticals INC. | $19.61 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.75 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.84 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.21 | 2021 | |
| Currax Pharmaceuticals LLC | $13.99 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.26 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajani Caesar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.